Skip to main content

Anesthesia, Intravenous

3
Pipeline Programs
4
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Orion Pharma
Orion PharmaUK - Reading
1 program
1
RemimazolamPhase 31 trial
Active Trials
NCT03661489Completed469Est. Apr 2020
Orion
OrionUK - Cambridge
1 program
1
RemimazolamPhase 3
Paion
PaionGermany - Aachen
1 program
1
RemimazolamPhase 3
B. Braun
B. BraunGermany - Melsungen
1 program
EdmonN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Orion PharmaRemimazolam

Clinical Trials (1)

Total enrollment: 469 patients across 1 trials

Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective Surgery

Start: Jul 2018Est. completion: Apr 2020469 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.